BioMarin Pharmaceutical Inc. Files 8-K Report
Ticker: BMRN · Form: 8-K · Filed: May 16, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | May 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing, financials
Related Tickers: BMRN
TL;DR
BioMarin inked a material definitive agreement, filing an 8-K on May 16, 2025.
AI Summary
On May 16, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and financial statements/exhibits. Specific details of the agreement, including parties involved and financial terms, were not elaborated upon in the provided text.
Why It Matters
This 8-K filing indicates BioMarin Pharmaceutical Inc. has entered into a significant agreement, which could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which inherently carries business and financial risks, but the specific nature of the agreement is not detailed.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- May 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 68-0397820 (identifier) — I.R.S. Employer Identification No.
- 770 Lindaro Street (address) — Principal Executive Offices
- San Rafael (city) — Principal Executive Offices
- California (state) — Principal Executive Offices
- 94901 (zip_code) — Principal Executive Offices
- (415) 506-6700 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by BioMarin Pharmaceutical Inc. on May 16, 2025?
The provided text states that BioMarin Pharmaceutical Inc. entered into a material definitive agreement, but does not specify the details of this agreement.
What other items are included in BioMarin Pharmaceutical Inc.'s 8-K filing dated May 16, 2025?
The filing includes Regulation FD Disclosure and Financial Statements and Exhibits, in addition to the material definitive agreement.
Where are BioMarin Pharmaceutical Inc.'s principal executive offices located?
BioMarin Pharmaceutical Inc.'s principal executive offices are located at 770 Lindaro Street, San Rafael, California 94901.
What is BioMarin Pharmaceutical Inc.'s telephone number?
BioMarin Pharmaceutical Inc.'s telephone number is (415) 506-6700.
In which state is BioMarin Pharmaceutical Inc. incorporated?
BioMarin Pharmaceutical Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 16, 2025 regarding BIOMARIN PHARMACEUTICAL INC (BMRN).